7 research outputs found

    ACTINOMYCIN “D” FROM MARINE SEDIMENT ASSOCIATED STREPTOMYCES CAPILLISPIRALIS MTCC10471

    Get PDF
    In our screening program for new bio-active metabolites from marine actinomycetes, a cyclic depsipeptide wasfound in the fermentation medium of marine Strepromyces (SS23/4) isolated from sediments collected from Bayoff Bengal, vellampattai,Tamilnadu. It showed strong biological activity against gram-positive / gram negativebacteria by agar overlay technique. It was taxonomically characterized by the basis of morphological andphenotypic characteristics, genotypic data and phylogenetic showing Streptomyces sps. Bio active compoundwas obtained by solvent extraction and purification using column chromatography followed by reverse phaseHPLC. The pure compound had potent activity against Mycobacterium tuberculosis and Multi Drug ResistantMycobacterium tuberculosis strains (437RU) at a concentration of 10 Îźg/mL, and The minimum inhibitoryconcentration (MIC) against standard test organisms was found to be 1Îźg/mL against B.subtilis, E.coli andMethicillin resistant Staphylococcus aureus. The compound exhibited potent cytotoxic activity against breastcarcinoma (MCF-7), melanoma cells (A375), prostate carcinoma (DU145) and lung carcinoma (A549) cellswith IC values 20Îźg/ml. The symbiotic Streptomyces capillispiralis MTCC 10471 produces crude antibiotic30mg/Lt by using nonoptimized fermentation conditions. The structure of the antibiotic was explained by 1D,2D NMR and LC-ESI-MS/MS, MALDI-TOF/MS experiments, revealed that it belongs to cyclic ploy peptideActinomycin D

    Bronchiectasis in India:results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry

    Get PDF
    BACKGROUND: Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income and middle-income countries. We therefore aimed to describe the characteristics, severity of disease, microbiology, and treatment of patients with bronchiectasis in India. METHODS: The Indian bronchiectasis registry is a multicentre, prospective, observational cohort study. Adult patients ( 6518 years) with CT-confirmed bronchiectasis were enrolled from 31 centres across India. Patients with bronchiectasis due to cystic fibrosis or traction bronchiectasis associated with another respiratory disorder were excluded. Data were collected at baseline (recruitment) with follow-up visits taking place once per year. Comprehensive clinical data were collected through the European Multicentre Bronchiectasis Audit and Research Collaboration registry platform. Underlying aetiology of bronchiectasis, as well as treatment and risk factors for bronchiectasis were analysed in the Indian bronchiectasis registry. Comparisons of demographics were made with published European and US registries, and quality of care was benchmarked against the 2017 European Respiratory Society guidelines. FINDINGS: From June 1, 2015, to Sept 1, 2017, 2195 patients were enrolled. Marked differences were observed between India, Europe, and the USA. Patients in India were younger (median age 56 years [IQR 41-66] vs the European and US registries; p<0\ub70001]) and more likely to be men (1249 [56\ub79%] of 2195). Previous tuberculosis (780 [35\ub75%] of 2195) was the most frequent underlying cause of bronchiectasis and Pseudomonas aeruginosa was the most common organism in sputum culture (301 [13\ub77%]) in India. Risk factors for exacerbations included being of the male sex (adjusted incidence rate ratio 1\ub717, 95% CI 1\ub703-1\ub732; p=0\ub7015), P aeruginosa infection (1\ub729, 1\ub710-1\ub750; p=0\ub7001), a history of pulmonary tuberculosis (1\ub720, 1\ub707-1\ub734; p=0\ub7002), modified Medical Research Council Dyspnoea score (1\ub732, 1\ub725-1\ub739; p<0\ub70001), daily sputum production (1\ub716, 1\ub703-1\ub730; p=0\ub7013), and radiological severity of disease (1\ub703, 1\ub701-1\ub704; p<0\ub70001). Low adherence to guideline-recommended care was observed; only 388 patients were tested for allergic bronchopulmonary aspergillosis and 82 patients had been tested for immunoglobulins. INTERPRETATION: Patients with bronchiectasis in India have more severe disease and have distinct characteristics from those reported in other countries. This study provides a benchmark to improve quality of care for patients with bronchiectasis in India. FUNDING: EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European Respiratory Society, and the British Lung Foundation

    Medicinal plants utilized in Thai Traditional Medicine for diabetes treatment: Ethnobotanical surveys, scientific evidence and phytochemicals

    No full text
    corecore